TEPANIL TEN-TAB (diethylpropion hydrochloride) by Teva is clinical pharmacology diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Approved for the management of exogenous obesity, higher. First approved in 1977.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
TEPANIL TEN-TAB (diethylpropion hydrochloride) is a sympathomimetic amine oral anorectic approved in 1977 for management of exogenous obesity. It works through central nervous system stimulation and appetite suppression, with complex metabolism producing multiple active metabolites that contribute to weight loss effects.
This product faces imminent loss of exclusivity with moderate competitive pressure (30%), signaling a contracting team focused on generic transition and retention strategies rather than growth initiatives.
CLINICAL PHARMACOLOGY Diethylpropion hydrochloride is a sympathomimetic amine with some pharmacologic activity similar to that of the prototype drugs of this class used in obesity, the amphetamines. Actions include some central nervous system stimulation and elevation of blood pressure. Tolerance…
Worked on TEPANIL TEN-TAB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
This is a mature legacy product with minimal career growth potential; open positions reflect turnover and retention needs rather than expansion. Working on TEPANIL TEN-TAB offers stability in a declining franchise but limited opportunity to drive innovation or advance to high-visibility roles.